Zevalin Becomes Available in Canada for Relapsed or Refractory Non-Hodgkin’s Lymphomas
News
Patients in Canada with relapsed or refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma, who produce the CD20 factor, can now be treated with Zevalin (ibritumomab tiuxetan). Servier Canada, Zevalin’s manufacturer, ... Read more